Adcytherix

Adcytherix is a clinical-stage biopharmaceutical company based in Marseille, France.

It focuses on developing next-generation antibody-drug conjugates (ADCs) aimed at treating cancers with high unmet medical needs, particularly those resistant to existing therapies. The company was founded in June 2024 by a team with a successful track record in the biopharmaceutical industry. Adcytherix is advancing a pipeline of novel ADC candidates, with its lead product, ADCX-020, currently in an open-label Phase 1 clinical trial for patients with advanced solid tumors. The company utilizes its proprietary ADCX Engine, which combines approved cancer drugs with innovative payloads to create effective treatments. Adcytherix is committed to addressing significant medical needs in oncology through its internal research and development, translational research, and clinical trial management.